Development of mammalian production cell lines expressing CNTO736, a Glucagon like peptide-1-MIMETIBODY™: Factors that influence productivity and product quality

Biotechnology and Bioengineering

Volumn 103, Issue 1, 2009, Pages 162-176

  Dorai, Haimanti ^a   Nemeth, Jennifer F ^a   Cammaart, Erwin ^a   Wang, Yonghui ^a   Tang, Qing Mike ^a   Magill, Allen ^a   Lewis, Michael J ^a   Raju, T Shantha ^a   Picha, Kristen ^a   O'Neil, Karyn ^a   Ganguly, Subinay ^a   Moore, Gordon ^a  

^a CENTOCOR INC   (United States)

Author keywords

CHO; HEK 293; Mammalian expression; Mammalian glycosylation; Mass spectrometry; MIMETIBODY ; N terminal clipping; NS0

Indexed keywords

CHO; HEK-293; MAMMALIAN EXPRESSION; MAMMALIAN GLYCOSYLATION; N-TERMINAL CLIPPING; NS0;

AMINES; ANIMAL CELL CULTURE; CELLS; CLONING; DEGRADATION; ESTERIFICATION; GLYCOSYLATION; MAMMALS; MASS SPECTROMETERS; MASS SPECTROMETRY; QUALITY CONTROL; SPECTRUM ANALYSIS;

CELL CULTURE;

CNT 0736; GLUCAGON LIKE PEPTIDE 1 RECEPTOR; HYBRID PROTEIN; MIMETIBODY; RECOMBINANT PROTEIN; UNCLASSIFIED DRUG; CNTO 736;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CELL CULTURE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG HALF LIFE; DRUG PURIFICATION; HUMAN; HUMAN CELL; IN VIVO STUDY; MOUSE; MYELOMA CELL; NONHUMAN; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN GLYCOSYLATION; ANIMAL; BIOSYNTHESIS; BIOTECHNOLOGY; CELL LINE; HAMSTER; METHODOLOGY;

MAMMALIA;

ANIMALS; BIOTECHNOLOGY; CELL LINE; CRICETINAE; HUMANS; MICE; RECOMBINANT FUSION PROTEINS;

EID: 64749098836     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.22217     Document Type: Article

References (51)

1. Anderson D, Goochee CF. 1994. The effect of cell-culture conditions on the oligosaccharide structures of secreted glycoproteins. Curr Opin Biotechnol 5:546-549.
2. Block H, Kubicek J, Labahn J, Roth U, Schäfer F. 2008. Production and comprehensive quality control of recombinant human Interleukin-1beta: A case study for a process development strategy. Protein Expr Purif 57:244-254.
3. Bond JS, Butler PE. 1987. Intracellular proteases. Ann Rev Biochem 56:333-364.
4. Chen P, Harcum SW. 2005. Effects of amino acid additions on ammonium stressed CHO cells. J Biotechnol 117:277-286.
5. Cohen SL, Price C, Vlasak J. 2007. Beta-elimination and peptide bond hydrolysis: Two distinct mechanisms of human IgG1 hinge fragmentation upon storage. J Am Chem Soc 129:6976-6977.
6. Cox KM, Sterling JD, Regan JT, Gasdaska JR, Frantz KK, Peele CG, Black A, Passmore D, Moldovan-Loomis C, Srinivasan M, Cuison S, Cardarelli PM, Dickey LF. 2006. Glycan optimization of a human monoclonal antibody in the aquatic plant Lemna minor. Nat Biotechnol 24:1591-1597.
7. Deo YM, Mahadevan MD, Fuchs R. 1996. Practical considerations in operation and scale-up of spin-filter based bioreactors for monoclonal antibody production. Biotechnol Prog 12:57-64.
8. Dwek RA, Lellouch AC, Wormald MR. 1995. Glycobiology: "The function of sugar in the IgG molecule". J Anat 187:279-292.
9. Ebert KM, Selgrath JP, DiTullio P, Denman J, Smith TE, Memon MA, Schindler JE, Monastersky GM, Vitale JA, Gordon K. 1991. Transgenic production of a variant of human tissue-type plasminogen activator in goat milk: Generation of transgenic goats and analysis of expression. Biotechnology (NY) 9:835-838.
10. Elliott P, Hohmann A, Spanos J. 2003. Protease expression in the supernatant of Chinese hamster ovary cells grown in serum-free culture. Biotechnol Lett 25:1949-1952.
11. Elliott S, Lorenzini T, Asher S, Aoki K, Brankow D, Buck L, Busse L, Chang D, Fuller J, Grant J, Hernday N, Hokum M, Hu S, Knudten A, Levin N, Komorowski R, Martin F, Navarro R, Osslund T, Rogers G, Rogers N, Trail G, Egrie J. 2003. Enhancement of a therapeutic protein in vivo activities through glycoengineering. Nat Biotechnol 21:414-421.
12. Finley EM, Kornfeld S. 1994. Subcellular localization of cathepsin E. J Biol Chem 269:31259-31266.
13. Gawlitzek M, Valley U, Wagner R. 1998. Ammonium ion and glucosamine dependent increases of oligosaccharide complexity in recombinant glycoproteins secreted from cultivated BHK-21 cells. Biotechnol Bioeng 57:518-528.
14. Gawlitzek M, Ryll T, Lofgren J, Sliwkowski MB. 2000. Ammonium alters N-glycan structures of recombinant TNFR-IgG: Degradative versus biosynthetic mechanisms. Biotechnol Bioeng 68:637-646.
15. Gerrngross TU. 2004. Advances in the production of human therapeutic proteins in yeasts and filamentous fungi. Nat Biotechnol 22:1409-1414.
16. Goochee CF, Gramer MJ, Andersen DJ, Bahr JB, Rasmussen JR. 1991. The oligosaccarides of glycoproteins: Bioprocess factors affecting oligosaccharide structure and their effect on glycoprotein properties. Bio/Technology 9:1347-1355.
17. Gramer MJ, Goochee CF. 1993. Glycosidase activities in CHO cell lysates and culture supernatants. Biotechol Prog 9:366-373.
18. Hahn T, Goochee CF. 1992. Growth-associated glycosylation of transferrin secreted by HepG2 cells. J Biol Chem 267:23982-23987.
19. Jones D, Kroos N, Anema R, van Montfort B, Vooys A, van der Kraats S, van der Helm E, Smits S, Schouten J, Brouwer K, Lagerwerf F, van Berkel P, Opstelten DJ, Logtenberg T, Bout A. 2003. High-level expression of recombinant IgG in the human cell line per.c6. Biotechnol Prog 19:163-168.
20. Karpuas M, Whitty A, Runkel L, Hochman P. 1998. The structure of human interferon-beta: Implications of activity. Cell Mol Life Sci 54:1213-1216.
21. Knight DM, Trinh H, Le J, Siegel S, Shealy D, McDonough M, Scallon B, Moore MA, Vilckeck J, Daddonna P. 1993. Construction and initial characterization of a mouse-human chimeric anti-TNF antibody. Mol Immunol 30:1443-1453.
22. Kronman C, Chitralu T, Elhanany E, Velan B, Scafferman A. 2000. Heirarchy of post-translational modifications involved in the circulatory longevity of glycoproteins. J Biol Chem 275:29488-229502.
23. Labbos J, Bradsher J, Kirkpatrick P. 2003. Drotrecogin alpha (activated). Nat Rev Drug Disc 2:13-14.
24. Lifely MR, Hale C, Boyce S, Keen MJ, Phillips J. 1995. Glycosylation and biological activity of CAMPATH-1H, expressed in different cell lines and grown under different culture conditions. Glycobiology 5:813-822.
25. Liu DT. 1992. Glycoprotein pharmaceuticals: Scientific and regulatory considerations, and the US Orphan Drug Act. Trends Biotechnol 10:114-120.
26. Noguchi A, Mukuria CJ, Suzuki E, Naiki M. 1995. Immunogenicity of N-glycolylneuraminic acid-containing carbohydrate chains of recombinant human erythropoietin expressed in Chinese hamster ovary cells. J Biochem 117:59-62.
27. Ozturk SS, Riley MR, Palsson BO. 1992. Effects of ammonia and lactate on hybridoma growth, metabolism, and antibody production. Biotechnol Bioeng 39:418-431.
28. Park M, Tenner AJ. 2003. Cell surface expression of C1qRp/CD93 is stabilized by O-glycosylation. J Cell Physiol 196:512-522.
29. Patel TP, Parekh RB, Moellering BJ, Prior CP. 1992. Culture methods lead to differences in glycosylation of a murine monoclonal antibody. Biochem J 285:839-845.
30. Picha KM, Cunningham MR, Drucker DJ, Mathur A, Ort T, Scully M, Soderman A, Spinka-Doms T, Stojanovic-Susulic V, Thomas BA, O'Neil KT. 2008. Protein engineering strategies for sustained glucagon-like peptide-1 receptor-dependent control of glucose homeostasis. Diabetes 57:1926-1934.
31. Prati EG, Matasci M, Suter TB, Dinter A, Sburlati AR, Bailey JE. 2002. Engineering of coordinated up- and down-regulation of two glycosyltransferases of the O-glycosylation pathway in Chinese hamster ovary (CHO) cells. Biotechnol Bioeng 79:580-585.
32. Raju TS, Scallon BJ. 2006. Glycosylation in the Fc domain of IgG increases resistance to proteolytic cleavage by papain. Biochem Biophys Res Commun 341:797-803.
33. Rutledge EA, Enns CA. 1996. Cleavage of the transferrin receptor is influenced by the composition of the O-linked carbohydrate at position 104. J Cell Physiol 168:284-293.
34. Sandberg H, Lütkemeyer D, Kuprin S, Wrangel M, Almstedt A, Persson P, Ek V, Mikaelsson M. 2006. Mapping and partial characterization of proteases expressed by a CHO production cell line. Biotechnol Bioeng 95:961-971.
35. Sheeley DM, Merrrill BM, Taylor LCE. 1997. Characterization of monoclonal antibody glycosylation: Comparison of expression systems and identification of terminal a-linked galactose. Anal Biochem 247:102-110.
36. Spiro MJ, Spiro RG. 1991. Potential regulation of N-glycosylation precursor through oligosaccharide-lipid hydrolase action and glucosyltransferase-glucosidase shuttle. J Biol Chem 266:5311-5317.
37. Squires C, Retalllack D, Chew L, Ramsmeier T, Scneider J, Talbot H. 2004. Heterologous protein production in Pseudomonas fluoescens. BioProcess Int/Tech (Issue Dec 2004): 454-460.
38. Stanley P. 1992. Glycosylation engineering. Glycobiology 2:99-107.
39. Tangvoranuntakul P, Gagneux P, Diaz S, Bardor M, Varki N, Varki A, Muchmore E. 2003. Human uptake and incorporation of an immunogenic nonhuman dietary sialic acid. Proc Nat Acad Sci USA 100:12145-12149.
40. Thorens B, Vassali P. 1986. Cloroquine and ammonium chloride prevent terminal glycosylation of immunoglobulins in plasma cells without affecting secretion. Nature 321:618-620.
41. Usdin S. 2008. A liter dissimilar. BioCentury 16:A1.
42. Varki A. 1993. Biological roles of oligosaccharides: All of the theories are correct. Glycobiology 3:99-107.
43. Varki A, Cummings R, Esko J, Freeze H, Hart G, Marth JD. 1999. O-Glycans. In 'essentials of glycobiology'. New York: Cold Spring Harbor Laboratory Press. pp. 101-113.
44. Walsh G. 2005. Biopharmaceuticals: Recent approvals and likely directions. Trends Biotechnol 23:553-558.
45. Weikert S, Papac D, Briggs J, Cowfer D, Tom S, Logfren J, Mehta S, Chisholm V, Modi N, Eppler S, Berman P, Krummen L. 1999. Engineering CHO cells to maximize sialic acid content of recombinant glycoproteins. Nat Biotechol 17:1116-1121.
46. Werner RG, Kopp K, Schlueter M. 2007. Glycosylation of therapeutic proteins in different production systems. Acta Paediatr Suppl 96:17-22.
47. Wright A, Shin SU, Morrison SL. 1992. Genetically engineered antibodies: Progress and prospects. Crit Rev Immunol 12:125-168.
48. Wurm F. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22:1393-1398.
49. Yang M, Butler M. 2002. Effects of ammonia and glucosamine on the heterogeneity of erythropoietin glycoforms. Biotechnol Prog 18:129-138.
50. Zanghi JA, Mendoza TP, Schmelzer AE, Knop RH, Miller WM. 1998. Role of nucleotide sugar pools in the inhibition of NCAM polysialylation by ammonia. Biotechnol Prog 14:834-844.
51. Zhu L, van der Lavoir MC, Albanese J, et al. 2005. Production of human monoclonal antibody in eggs of chimeric chickens. Nat Biotechnol 23:1159-1169.